Trial · NCT02709018
A Controlled Trial of Losartan in Posttraumatic Stress Disorder
NCT02709018, Not applicable, Completed, University of California, San Diego; results first posted 2021-03-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Controlled Trial of Losartan in Posttraumatic Stress Disorder. Trials, record NCT02709018. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02709018
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Controlled Trial of Losartan in Posttraumatic Stress Disorder
- NCT number
- NCT02709018
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 149 participants, actual
- Lead sponsor
- University of California, San Diego
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- losartan, Placebo
- First posted
- 2016-03-15
- Last updated
- 2021-03-12
- Results first posted
- 2021-03-12
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm. | 10 weeks | Clinician-Administered PTSD Scale for DSM-5 also known as CAPS-5 is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to, make current (past month) diagnosis of PTSD, make a lifetime diagnosis of PTSD and assess PTSD symptoms over the past week. The CAPS-5 as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome. |
| Secondary | Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan. | 10 weeks | The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm. | 10 weeks | Modified Intent to Treat (mITT) Population | score on a scale | MEAN |
| SECONDARY | Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan. | 10 weeks | Subjects on Losartan Arm | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm. | Losartan | -15.96 | 95% Confidence Interval -18.86 to -13.06 | score on a scale | |
| The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm. | Placebo | -16.89 | 95% Confidence Interval -19.81 to -13.97 | score on a scale | |
| Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan. | CC Homozygotes on Losartan | 16.7 | Standard Deviation 10.1 | score on a scale | |
| Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan. | T Carriers on Losartan | 15.8 | Standard Deviation 13.1 | score on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Losartan | 75 | |
| Overall Study | STARTED | Placebo | 74 | |
| Overall Study | COMPLETED | Losartan | 59 | |
| Overall Study | COMPLETED | Placebo | 58 | |
| Overall Study | NOT COMPLETED | Losartan | 16 | |
| Overall Study | NOT COMPLETED | Placebo | 16 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Lightheadedness | Nervous system disorders | Losartan | 8 | 75 | 13 |
| other | Lightheadedness | Nervous system disorders | Placebo | 7 | 74 | 9 |
| other | Insomnia | Nervous system disorders | Losartan | 4 | 75 | 4 |
| other | Insomnia | Nervous system disorders | Placebo | 5 | 74 | 5 |
| other | headache | Nervous system disorders | Losartan | 16 | 75 | 24 |
| other | headache | Nervous system disorders | Placebo | 14 | 74 | 21 |
| serious | Neurosyphilis | Nervous system disorders | Losartan | 0 | 75 | 0 |
| serious | Neurosyphilis | Nervous system disorders | Placebo | 1 | 74 | 1 |
| serious | Cataplexy | Nervous system disorders | Losartan | 1 | 75 | 1 |
| serious | Cataplexy | Nervous system disorders | Placebo | 0 | 74 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Losartan | 0 | 75 |
| Total, all-cause mortality | Placebo | 0 | 74 |
| Total, other adverse events | Losartan | 20 | 75 |
| Total, other adverse events | Placebo | 18 | 74 |
| Total, serious adverse events | Losartan | 2 | 75 |
| Total, serious adverse events | Placebo | 1 | 74 |
Source ClinicalTrials.gov
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Losartan vs Placebo: deaths from any cause | Trial comparisons |
| Losartan vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02709018
GET https://conductscience.org/api/trials/v1/NCT02709018/registered